Chronic rhinosinusitis with nasal polyps presents a substantial clinical burden, affecting nasal airflow, olfactory function, ...

Clinicians have a new line of weapons in their arsenal to treat recurring nasal polyps. Over the past year several new monoclonal antibody-based biologic drugs have been approved to treat the ...

Study uncovers a pathogenic subset of memory T-cells that promote tissue inflammation and highlights a potential target for treating nasal polyps and other inflammatory airway diseases. Study: ...

Of the 6,137 pathological reports that were reviewed, 4,328 patients with endocervical polyps were identified. Most of the patients (3,656, 84.5%) had polyps reported as endocervical polyp without ...

(Reuters) -The U.S. Food and Drug Administration has approved Amgen and AstraZeneca's drug for a type of chronic inflammatory sinus disease, the drugmakers said on Friday. The approval expands the use ...

Approval broadens indication for TEZSPIRE to a second disease characterized by epithelial-driven inflammation AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab -ekko) has been approved in the US for the ...

A Canadian real-world study reveals high oral corticosteroid exposure in patients with severe chronic rhinosinusitis with ...

If you’re living with nasal polyps, you know how frustrating they can be, with constant congestion, facial pressure, and that annoying loss of smell. While treatment from your doctor is important, ...